Researchers have published results of experiments in rodents suggesting that lithium, a widely prescribed mood stabilizer, may have value as an adjunct to ketamine therapy in people who suffer from ...
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for ...
Please provide your email address to receive an email when new articles are posted on . AL001 by Alzamend Neuro will undergo a phase 2a trial in patients with major depressive disorder. The ...
Augmentation was more effective with quetiapine than lithium for treatment-resistant depression in a pragmatic trial. Quetiapine also improved quality-adjusted life years more than lithium. The ...
Lithium is one of the good substitute for antidepressants and is effective for long-term treatment of depression and bipolar disorder, offering mood stabilization and anti-suicidal effects. It reduces ...
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for ...
A nationwide Swedish cohort study included 105,495 individuals (mean age, 44.2 years; 62.2% women) diagnosed with bipolar disorder between 2006 and 2021 using data from national registers of inpatient ...
Approximately 30% of people with major depression, have treatment-resistant depression, meaning it doesn’t respond to first and second-line antidepressants prescribed. While older people aren’t more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback